X4 PHARMACEUTICALS INC's ticker is XFOR and the CUSIP is 98420X103. A total of 55 filers reported holding X4 PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 1.29 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,718 | -94.8% | 1,576 | -90.8% | 0.00% | – |
Q2 2023 | $33,236 | +553833.3% | 17,132 | +285433.3% | 0.00% | – |
Q1 2023 | $6 | -100.0% | 6 | -99.9% | 0.00% | – |
Q3 2022 | $17,000 | -86.0% | 10,000 | -81.1% | 0.00% | – |
Q4 2021 | $121,000 | -85.0% | 53,031 | -65.3% | 0.00% | – |
Q3 2021 | $808,000 | -41.5% | 152,831 | -28.1% | 0.00% | – |
Q2 2021 | $1,382,000 | -24.5% | 212,620 | 0.0% | 0.00% | – |
Q1 2021 | $1,831,000 | +33.9% | 212,620 | 0.0% | 0.00% | – |
Q4 2020 | $1,367,000 | -9.0% | 212,620 | -4.2% | 0.00% | – |
Q3 2020 | $1,502,000 | -76.9% | 221,912 | -68.2% | 0.00% | -100.0% |
Q2 2020 | $6,503,000 | -6.8% | 697,800 | 0.0% | 0.00% | 0.0% |
Q1 2020 | $6,978,000 | -27.5% | 697,800 | -22.5% | 0.00% | 0.0% |
Q4 2019 | $9,630,000 | -15.8% | 900,000 | 0.0% | 0.00% | 0.0% |
Q3 2019 | $11,439,000 | -15.3% | 900,000 | 0.0% | 0.00% | -50.0% |
Q2 2019 | $13,500,000 | – | 900,000 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Polaris Venture Management Co. V, L.L.C. | 311,492 | $2,109,000 | 3.48% |
SV Health Investors, LLC | 311,490 | $2,109,000 | 1.07% |
Bain Capital Life Sciences Investors, LLC | 1,648,485 | $11,160,000 | 1.04% |
New Leaf Venture Partners, L.L.C. | 335,000 | $2,268,000 | 0.91% |
Ikarian Capital, LLC | 724,680 | $4,907,000 | 0.36% |
BVF INC/IL | 792,892 | $5,368,000 | 0.29% |
Opaleye Management Inc. | 75,000 | $508,000 | 0.10% |
Orbimed Advisors | 1,086,493 | $7,356,000 | 0.09% |
RA Capital Management | 559,494 | $3,788,000 | 0.07% |
Bleichroeder LP | 35,730 | $242,000 | 0.04% |